How Do Bisphosphonates Inhibit Bone Metastasis In Vivo

by Pierrick G. Fournier, Verena Stresing, Frank H. Ebetino, Philippe Clezardin
Published 2010-07-01

Bisphosphonate use in the horse: what is good and what is not?

by Alexis Mitchell, Ashlee E. Watts, Frank H. Ebetino, Larry J. Suva
Published 2019-06-01

A Bisphosphonate With a Low Hydroxyapatite Binding Affinity Prevents Bone Loss in Mice After Ovariectomy and Reverses Rapidly With Treatment Cessation

by Abigail A Coffman, Jelena Basta‐Pljakic, Rosa M Guerra, Frank H Ebetino, Mark W Lundy, Robert J Majeska, Mitchell B Schaffler
Published 2021-04-01

Reply to: A Bisphosphonate With a Low Hydroxyapatite Binding Affinity Prevents Bone Loss in Mice After Ovariectomy and Reverses Rapidly With Treatment Cessation

by Abigail A Coffman, Jelena Basta‐Pljakic, Rosa M Guerra, Frank H Ebetino, Mark W Lundy, Robert J Majeska, Mitchell B Schaffler
Published 2021-07-01

Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice

by Hua Wang, Lifeng Xiao, Jianguo Tao, Venkat Srinivasan, Brendan F. Boyce, Frank H. Ebetino, Babatunde O. Oyajobi, Robert K. Boeckman, Lianping Xing
Published 2018-09-01

Development of Bisphosphonate-Conjugated Antibiotics to Overcome Pharmacodynamic Limitations of Local Therapy: Initial Results with Carbamate Linked Sitafloxacin and Tedizolid

by Emmanuela Adjei-Sowah, Yue Peng, Jason Weeks, Jennifer H. Jonason, Karen L. de Mesy Bentley, Elysia Masters, Yugo Morita, Gowrishankar Muthukrishnan, Philip Cherian, X. Eric Hu, Charles E. McKenna, Frank H. Ebetino, Shuting Sun, Edward M. Schwarz, Chao Xie
Published 2021-06-01